Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Turns To Ventana To Expand Companion Dx Options For Xalkori

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer has partnered with Ventana to develop a second companion diagnostic to test for ALK gene mutations to identify patients who could benefit from treatment with Xalkori.


Related Content

Device/Diagnostics Quarterly Deal Statistics, Q1 2012
Synchronized Regulation: Tandem Approvals Of Xalkori, Diagnostic Required Considerable Coordination
Xalkori And The Art Of Modern Drug Development
European Regulatory Round-Up: New Faces; Revised Guidances; More Cost Controls
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts